HoxA9 regulated Bcl-2 expression mediates survival of myeloid progenitors and the severity of HoxA9-dependent leukemia.
about
Role of HOXA9 in leukemia: dysregulation, cofactors and essential targetsBCL-2 is dispensable for thrombopoiesis and platelet survivalProsurvival Bcl-2 family members affect autophagy only indirectly, by inhibiting Bax and Bak.The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia.A transcriptomic signature mediated by HOXA9 promotes human glioblastoma initiation, aggressiveness and resistance to temozolomideCCI-007, a novel small molecule with cytotoxic activity against infant leukemia with MLL rearrangements.Higher expression levels of the HOXA9 gene, closely associated with MLL-PTD and EZH2 mutations, predict inferior outcome in acute myeloid leukemia.Molecular synergy underlies the co-occurrence patterns and phenotype of NPM1-mutant acute myeloid leukemia.HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia.HOXB7 promotes tumor progression via bFGF-induced activation of MAPK/ERK pathway and indicated poor prognosis in hepatocellular carcinoma.CDK4/6 Inhibitor PD 0332991 Sensitizes Acute Myeloid Leukemia to Cytarabine-Mediated Cytotoxicity.Dysregulation of BCL-2 family proteins by leukemia fusion genes.Overexpression of NAC1 confers drug resistance via HOXA9 in colorectal carcinoma cells.MicroRNA-182 downregulates Wnt/β-catenin signaling, inhibits proliferation, and promotes apoptosis in human osteosarcoma cells by targeting HOXA9.A dual role for the N-terminal domain of the IL-3 receptor in cell signalling.Insulin-like growth factor 1 is a direct HOXA9 target important for hematopoietic transformation.HOXA9 inhibits HIF-1α-mediated glycolysis through interacting with CRIP2 to repress cutaneous squamous cell carcinoma development.
P2860
Q28082027-606F6E03-85CE-4B80-A806-506DFFF6C1B9Q33422077-2B320562-15C4-474C-A936-DBBB4BEF761CQ33767555-C3310985-7281-41A3-A3B8-4C64C718095DQ34527239-6A89EB36-DBA3-4060-B5AC-2D3FE240D514Q35781382-D6B7A0E1-54FE-4531-AFB5-616320915CF0Q36056038-6E492DFB-B6A2-4E42-A416-FBE15C7EAFF0Q36585150-34130034-E5E5-4B6E-A56F-5484226B0B0CQ38429500-D7DB3A96-0A70-4E1F-9F33-9B25AD7A2F7CQ38753227-2F13B138-4F9E-43DA-89A7-702DF157E094Q38814227-18C1C35F-1A6C-4469-BEE0-7C75471788D0Q38903073-7D7F65FD-5859-4016-B192-349345D52981Q39440247-DC6EB86C-711F-458A-9D8A-C4C3DBEEEE80Q42546855-71197819-47A1-4A56-988E-C03F1F827E7AQ47099829-CB8E320B-DCB9-4DF5-AD36-4896432EF46DQ48158203-5A3D1440-2566-48CD-B8E1-73C3B1EF1DB4Q48267075-9A06F6A3-8EE1-47C1-9A77-BAA2E5FF7E50Q52584615-B4CD71AB-5F87-488B-B7D8-60C681F5F7CE
P2860
HoxA9 regulated Bcl-2 expression mediates survival of myeloid progenitors and the severity of HoxA9-dependent leukemia.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
HoxA9 regulated Bcl-2 expressi ...... y of HoxA9-dependent leukemia.
@en
HoxA9 regulated Bcl-2 expressi ...... y of HoxA9-dependent leukemia.
@nl
type
label
HoxA9 regulated Bcl-2 expressi ...... y of HoxA9-dependent leukemia.
@en
HoxA9 regulated Bcl-2 expressi ...... y of HoxA9-dependent leukemia.
@nl
prefLabel
HoxA9 regulated Bcl-2 expressi ...... y of HoxA9-dependent leukemia.
@en
HoxA9 regulated Bcl-2 expressi ...... y of HoxA9-dependent leukemia.
@nl
P2093
P2860
P356
P1433
P1476
HoxA9 regulated Bcl-2 expressi ...... y of HoxA9-dependent leukemia.
@en
P2093
Anissa M Jabbour
Chung H Kok
Gabriela Brumatti
Jarrod J Sandow
Jolanda Visser
Kylie Mason
Marika Salmanidis
Natasha Silke
Rebecca A Bilardi
Richard J D'Andrea
P2860
P304
P356
10.18632/ONCOTARGET.1306
P407
P577
2013-11-01T00:00:00Z